Drugs / OSE2101
Trials 7 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT05751798 | Dec 2022 → Dec 2029 expected | lymphoma, non-small cell lung carcinoma | OSE Immunotherapeutics | Recruiting | No outcome recorded |
| Phase 24 trials | ||||||
| Phase 2 | NCT07264673 | Apr 2025 → Oct 2027 expected | non-small cell lung carcinoma | Fondazione Ricerca Traslazionale | Recruiting | No outcome recorded |
| Phase 2 | NCT04884282 | Oct 2021 → Sep 2027 expected | non-small cell lung carcinoma | Fondazione Ricerca Traslazionale | Active not recruiting | No outcome recorded |
| Phase 2 | NCT04713514 | Aug 2021 → Dec 2025 overdue | — | ARCAGY/ GINECO GROUP | Active not recruiting | No outcome recorded |
| Phase 2 | NCT03806309 | Apr 2021 → Dec 2024 overdue | metastatic malignant neoplasm, pancreatic ductal adenocarcinoma | GERCOR - Multidisciplinary Oncology Cooperative Group | Active not recruiting | No outcome recorded |
| Phase 32 trials | ||||||
| Phase 3 | NCT06472245 | Dec 2024 → Dec 2027 expected | non-small cell lung carcinoma | OSE Immunotherapeutics | Recruiting | No outcome recorded |
| Phase 3 | NCT02654587 | Feb 2016 → Jan 2021 | non-small cell lung carcinoma | OSE Immunotherapeutics | Terminated | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 7 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | OSE2101 | “Cemiplimab + OSE2101 (TEDOPI®) (ARM B: experimental arm)” NCT07264673 ↗ |
| Known as | TEDOPI | “Cemiplimab + OSE2101 (TEDOPI®) (ARM B: experimental arm)” NCT07264673 ↗ |
| Modality | Vaccine | “therapeutic cancer vaccine OSE2101” NCT02654587 ↗ |
| Route | Subcutaneous | “OSE2101 was administered as a 1 mL-subcutaneous injection” NCT02654587 ↗ |